| |  Online-Ressource |
|---|
| Verfasst von: | Brinkmann, Berit J. [VerfasserIn]  |
|---|
| | Floerchinger, Alessia [VerfasserIn] |
|---|
| | Schniederjohann, Christina [VerfasserIn] |
|---|
| | Roider, Tobias [VerfasserIn] |
|---|
| | Coelho, Mariana [VerfasserIn] |
|---|
| | Mack, Norman [VerfasserIn] |
|---|
| | Bruch, Peter-Martin [VerfasserIn] |
|---|
| | Liebers, Nora [VerfasserIn] |
|---|
| | Dötsch, Sarah [VerfasserIn] |
|---|
| | Busch, Dirk H. [VerfasserIn] |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| | Neumann, Frank [VerfasserIn] |
|---|
| | Rößner, Philipp M. [VerfasserIn] |
|---|
| | Seiffert, Martina [VerfasserIn] |
|---|
| | Dietrich, Sascha [VerfasserIn] |
|---|
| Titel: | CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models |
|---|
| Verf.angabe: | Berit J. Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Norman Mack, Peter-Martin Bruch, Nora Liebers, Sarah Dötsch, Dirk H. Busch, Michael Schmitt, Frank Neumann, Philipp M. Roessner, Martina Seiffert, Sascha Dietrich |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | August 15, 2024 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 24.10.2024 |
|---|
| Titel Quelle: | Enthalten in: Blood |
|---|
| Ort Quelle: | Washington, DC : American Society of Hematology, 1946 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 144(2024), 7, Seite 784-789 |
|---|
| ISSN Quelle: | 1528-0020 |
|---|
| Abstract: | Relapse after anti-CD19 chimeric antigen receptor (CD19-CAR) occurs in a substantial proportion of patients with lymphoid malignancies. We assessed the potential benefits of co-administering CD20-targeting bispecific antibodies (CD20-BsAbs) with CD19-CAR T cells with the aim of enhancing immunotherapeutic efficacy. Addition of CD20-BsAbs to cocultures of CD19-CARs and primary samples of B-cell malignancies, comprising malignant B cells and endogenous T cells, significantly improved killing of malignant cells and enhanced the expansion of both endogenous T cells and CD19-CAR T cells. In an immunocompetent mouse model of chronic lymphocytic leukemia, relapse after initial treatment response frequently occurred after CD19-CAR T-cell monotherapy. Additional treatment with CD20-BsAbs significantly enhanced the treatment response and led to improved eradication of malignant cells. Higher efficacy was accompanied by improved T-cell expansion with CD20-BsAb administration and led to longer survival with 80% of the mice being cured with no detectable malignant cell population within 8 weeks of therapy initiation. Collectively, our in vitro and in vivo data demonstrate enhanced therapeutic efficacy of CD19-CAR T cells when combined with CD20-BsAbs in B-cell malignancies. Activation and proliferation of both infused CAR T cells and endogenous T cells may contribute to improved disease control. |
|---|
| DOI: | doi:10.1182/blood.2023022682 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1182/blood.2023022682 |
|---|
| | DOI: https://doi.org/10.1182/blood.2023022682 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1906731713 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models / Brinkmann, Berit J. [VerfasserIn]; August 15, 2024 (Online-Ressource)
